Trial intelligence / Profile preview

Panobinostat pharmacokinetics and safety in advanced solid tumors with varying renal function

NL-OMON36258Phase 1Active, not recruiting

Sponsor
Novartis
Start
Jun 2010
Modality
Small Molecules
Countries
1
01

Overview

Phase 1, open-label trial of panobinostat in Nonhematologic neoplasms (4 arms), sponsored by Novartis. Started Jun 2010; status: active, not recruiting.

02

Drugs

panobinostat
03

Conditions

Nonhematologic neoplasms

Beyond the preview

Go deeper on NL-OMON36258.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NL-OMON36258.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call